This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 FY27 revenue up 22.1%, profit after tax up 51.8%
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.6 pts less than Nifty Microcap 250 and 4.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
On a consolidated basis for the quarter ended 30 September 2026 versus 30 September 2025, revenue from operations rose 22.1% to Rs 74.89 crore from Rs 61.34 crore, while profit after tax rose 51.8% to Rs 18.55 crore from Rs 12.22 crore. EBITDA margin, before other income, interest, depreciation and tax, rose to about 39.9% from 33.5%. The limited review was unmodified.
Strong quarterly growth may support the stock; new products and capacity expansion add upside, while spending and working capital needs are risks.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹137.5 Cr | ₹203.6 Cr | −32.5% |
| Operating profit | ₹24.03 Cr | ₹26.11 Cr | −8.0% |
| Profit after tax | ₹19.28 Cr | — | — |
| EBITDA margin | 22.0% | — | — |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.